cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Mustofa
Contact Email
mustofafk@ugm.ac.id
Phone
+6281328749273
Journal Mail Official
mustofafk@ugm.ac.id
Editorial Address
Department of Pharmacology and Therapy Radioputro Building 2nd Floor Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada Jl. Farmako Sekip Utara, Yogyakarta 55281 Indonesia
Location
Kab. sleman,
Daerah istimewa yogyakarta
INDONESIA
Indonesian Journal of Pharmacology and Therapy
Published by Universitas Gadjah Mada
ISSN : -     EISSN : 2745455X     DOI : https://doi.org/10.22146/ijpther.10147
Core Subject : Health, Science,
Immunology & microbiology Medicine & Pharmacology
Indonesian Journal of Pharmacology and Therapy (IJPTher ) is a scientific journal which published by Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI). IJPTher is an open-access, and double-blind peer-reviewed journal published three Issues a year. IJPTher aims to communicate high-quality articles in the fields of pharmacology. IJPTher publishes original articles, review articles, case reports and book reviews in the fields of pharmacology including basic pharmacology, clinical pharmacology, pharmacotherapy, pharmacoepidemiology, pharmacogenetics, pharmacogenomics, pharmacoeconomic, toxicology and toxicogenomics.
Arjuna Subject : Pharmacology, Toxicology and Pharmaceutics - Pharmacology, Toxicology and Pharmaceutics (Lain-Lain)
Articles 5 Documents
 1 
Search results for , issue "Vol 6 No 2 (2025)" : 5 Documents clear
Evaluation of potential drug-drug interactions in stage 5 chronic kidney disease patients on routine hemodialysis at Dr. Cipto Mangunkusumo General Hospital, Jakarta Ulfa, Nusmirna; Soetikno, Vivian; Hustrini, Ni Made
Indonesian Journal of Pharmacology and Therapy Vol 6 No 2 (2025)
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.19437

Abstract

Patients with chronic kidney disease (CKD) face heightened susceptibility to adverse drug reactions (ADRs) owing to alterations in the pharmacokinetics and pharmacodynamics of medications. Patients with Stage 5 CKD receiving hemodialysis (HD) have numerous medications that are eliminated during the HD process. This study aims to assess the prescribing patterns in stage 5 CKD patients undergoing routine HD and their association with drug-drug interactions (DDIs) and the potential for adverse drug reactions (ADRs) resulting from DDIs. This cross-sectional study encompassed stage 5 CKD patients undergoing routine HD at Dr. Cipto Mangunkusumo General Hospital from 2020 to 2021. Data were obtained from the medical records of the HD Unit. An evaluation was performed utilizing the Lexicomp software to discover DDIs. The study had 147 individuals, with 101 different medications taken, the most prevalent being epoetin alfa (70.4%). Eighty nine percent of patients who underwent treatment associated with a potential DDIs, with the bulk of these interactions classified as moderate (88%). Fifty percent of patients were suspected of experiencing ADRs due to DDIs. Diabetes mellitus exhibited a statistically significant association with suspected ADRs attributable to DDIs (p = 0.04). Hypertension was the most predicted ADR resulting from DDIs, and diabetes mellitus significantly contributed to the incidence of ADRs owing to DDIs in patients with stage 5 CKD on routine HD. In conclusion, DDI in patients undergoing routine HD is sometimes unavoidable considering the many comorbidities. The DDI that occurred was moderate in severity and could be managed well at the Dr. Cipto Mangukusumo General Hospital.
Antibiotic use at the ear, nose, and throat outpatient clinic in Bangli Regional Hospital, Bali Sudiadewi, Ni Putu Eka; Permatananda, Pande Ayu Naya Kasih; Udiyani, Desak Putu Citra; Cahyawati, Putu Nita; Aryastuti, Sri Agung
Indonesian Journal of Pharmacology and Therapy Vol 6 No 2 (2025)
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.20992

Abstract

Ear, nose, and throat (ENT) diseases are defined as diseases that occur around the ear, nose, and throat organs, which do not recognize seasons and can affect various ages. The prevalence of ENT diseases in Indonesia is quite high, with the most common therapy being antibiotics. Irrational antibiotics use can lead to increased treatment costs, risk of side effects, and toxicity. This study aimed to evaluate the use of antibiotics among ENT outpatient. This was a cross-sectional study using medical records data from the ENT Outpatient Clinic in Bangli Regional Hospital in 2022 that meet the inclusion criteria. Data were analyzed descriptively and presented in tables or diagrams. A total of 80 samples were evaluated, predominantly aged 18-44 yo (60%), female (53.8%), and diagnosed with chronic suppurative otitis media (20%). The pattern of antibiotic prescription consisted of monotherapy antibiotics (62.5%) in solid dosage forms (58.8%), administered orally (60%), and with a duration of administration ≥ 5 d (82.5%). Patients aged 18-44 yr, both male and female, receiving either monotherapy orpolytherapy antibiotics were predominantly cases of infection (>90%). The results of this study are expected to serve as one of the sources of information for the development of practical clinical guidelines for ENT patients receiving antibiotic therapy, particularly at the Bangli Regional Hospital, Bali.
Antidimentia activity of instant granule containing a combination of Brassica oleracea L. Var. Italica and Centella asiatica L. Urban extracts in male mice (Mus musculus) model of dementia Erni Rustiani; Suci Sintya; Min Rahminiwati
Indonesian Journal of Pharmacology and Therapy Vol 6 No 2 (2025)
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.17391

Abstract

Dementia is a progressive cognitive impairment characterized by cognitive decline and memory loss. Acetylcholine levels in dementia patients decrease due to increased levels of acetylcholinesterase which breaks down acetylcholine into choline and acetate. Gotu kola (Centella asiatica L. Urban) contains asiaticoside,while broccoli (Brassica oleracea L. Var Italica) contains glucosinolate. Both compounds are believed to have acetylcholinesterase inhibitor activity. This study aimed to evaluate the antidementia activity of instant granules of a combination of B. oleracea and C. asiatica extracts in male white mice model of dementia. Thirty-five male mice were used in this experimental divided into seven group with five mice in each group. All groups were induced with hyoscine butylbromide intraperitoneally except the normal control group (group I). Group II (negative control) was given Na CMC 0.5% orally, and group III (positive control) was given piracetam intraperitoneally. Groups IV to VII were given instant granules with different formulation, namely namely group IV (25 mg :190 mg dose 1x), group V (25 mg : 190 mg dose 2x), group VI (190 mg : 190 mg dose 1x) and group VII (190 mg : 190 mg dose 2x). Y-maze test for mice was carried out for 5 min by allowing mice to explore the three arms of the Y-maze freely. A significant difference in antidementia activity between groups given the instant granules was observed (p <0.05). The instant granules combination with a ratio of B. oleracea andC. asiatica extracts (190 mg : 190 mg) had a higher antidementia activity than that combination of 25 mg : 190 mg. The instant granules combination with a ratio of B. oleracea and C. asiatica extracts (190 mg : 190 mg) at dose 2x had a higher antidementia activity than at dose 1x. In conclusion, the instant granules combination of B. oleracea and C. asiatica have a potential antidementia activity.
The quality of life (QoL) of advanced stage lung adenocarcinoma patients receiving afatinib at Dr. Sardjito General Hospital, Yogyakarta Bayu Prio Septiantoro; Retno Murwanti; Dyah Aryani Perwitasari; Mustofa
Indonesian Journal of Pharmacology and Therapy Vol 6 No 2 (2025)
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.20381

Abstract

Lung cancer has the highest mortality rate of all cancers. In its advanced stages, this disease is associated with poor survival rates and quality of life. The most common subtype of lung cancer is adenocarcinoma which is frequently associated with mutations in the epidermal growth factor receptor (EGFR), a protein crucialfor cell proliferation. The presence of EGFR mutations plays a key role in targeted therapy using tyrosine kinase inhibitors (TKIs). Afatinib is a second-generation TKI that offers several advantages over the first-generation. Afatinib is effective against complex and uncommon EGFR mutations, making it a commonly usedoption for patients with lung adenocarcinoma. However, afatinib is also associated with a higher incidence of adverse drug reactions (ADRs) compared to other TKIs, which may impact therapeutic outcomes. This study aimed to assess the quality of life (QoL) of advanced lung adenocarcinoma patients with EGFR mutations andthe prevalence of ADRs associated with afatinib treatment at Dr. Sardjito General Hospital in Yogyakarta. The study employed an observational cross-sectional design. Prospective data collection was conducted for two months, from January to February 2025 at the Oncology Department following ethical approval. A totalof 15 patients were enrolled in this study. The most commonly identified ADRs were acne (45%), diarrhea (20%), paronychia (20%), and oral mucositis (15%). The mean QoL scores was 81.38 ± 10.01 for the functional scale, 15.93 ± 8.48 for the symptom scale, and 72.78 ± 19.53 for global health status.
The pharmacokinetics of cefepime in various health conditions: a review article Viktaria, Venansi; Kusumasari, Dyah; Usni Putri, Saifa; Chintyasari, Shaula; Mustofa
Indonesian Journal of Pharmacology and Therapy Vol 6 No 2 (2025)
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.15937

Abstract

Cefepime is one of fourth-generation cephalosporins which has been proven to have activity against a wide spectrum of Gram-positive and Gram-negative bacterias. It induces lysis in bacterias by disrupting the cell wall synthesis. In this review, we presented the pharmacokinetic profile cefepime in subjects with various healthconditions, such as in healthy adults, in patients with hematological malignancies, in critically ill patients, as well as in patients with renal impairment. According to various studies, such conditions could alter the pharmacokinetic profile of cefepime, especially on the excretion profile. Nevertheless, it is concluded thatcefepime could still be given all subjects, either with and without underlying conditions.

Page 1 of 1 | Total Record : 5

 1 

Filter by Year

2025 2025


Reset
Filter By Issues
All Issue Vol 6 No 3 (2025) Vol 6 No 2 (2025) Vol 6 No 1 (2025) Vol 5 No 3 (2024) Vol 5 No 2 (2024) Vol 5 No 1 (2024) Vol 4 No 3 (2023) Vol 4 No 2 (2023) Vol 4 No 1 (2023) Vol 3 No 3 (2022) Vol 3 No 2 (2022) Vol 3 No 1 (2022) Vol 2 No 3 (2021): Special Issue: COVID-19 Vol 2 No 3 (2021) Vol 2 No 2 (2021) Vol 2 No 1 (2021) Vol 1 No 2 (2020) Vol 1 No 1 (2020) More Issue